Enpatoran, a TLR7/8 inhibitor, demonstrated clinically meaningful improvements in disease activity among patients with ...

Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity ...

Immunovant faces high R&D costs, limited cash runway, and unproven clinical edge despite pipeline progress and deeper IgG reductions. See why IMVT stock is a hold.

BOSTON, MA, USA I June 12, 2025 I EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

The Johns Hopkins Department of Dermatology is conducting a research study led by Dr. Jun Kang to better understand the cellular mechanisms driving disease activity and long-term skin damage in ...

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16 ...

Results will be presented at the 16 th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place May 21-24 in Toronto. WILLOW is a global, multicenter, randomized, ...

Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 ...